Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sessa, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sessa, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 2:727-731, 1991
© 1991 European Society for Medical Oncology

research-article

Original article: Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers

C. Sessa1,, F. Calabresi2, F Cavalli1, T. Cerny3, P. Liati4, T. Skovsgaard5, R. Sorio6, S. B. Kaye7 and For the Early Clinical Trials Group of the European Organization for Research and Treatment of Cancer

1Ospedale San Giovanni Bellinzona, Switzerland
2Istituto Regina Elena Roma, Italy
3Inselspital Bern, Switzerland
4Farmitalia Carlo Erba Milano, Italy
5Herlev Hospital Copenhagen, Denmark
6Centro di Riferimento Oncologico Aviano, Italy
7University of Glasgow Bearsden, Glasgow, U.K.

Correspondence to: Cristiana Sessa, M.D., Servizio Oncologico, Ospedale San Giovanni, 6500 Bellinzona, Switzerland

The new anthracycline analogue, 4'-iodo-4'-deoxydoxorubicin (I-DOX), was administered at 70 mg/m2as first chemotherapy in 61 patients with advanced NSCL (19), colon (20) and breast cancers (22). Treatment was repeated every 3 weeks; the dose was decreased to 60 mg/m2(19% of the cycles) or increased to 80 mg/m2(17% of the cycles) according to the granulocyte count nadir. Partial responses were observed in 6% of the patients with NSCL, in 5.5% of those with colon and in 10% of those with breast cancers. The main toxicity was a selective gra-nulocytopenia characterized by a duration of about 1 week, and a high inter-patient variability. Non-haematologi-cal toxicities were mild. The negative results obtained in breast cancer might be related to the dose administered. Further studies in this tumour type should be performed with a more aggressive schedule.

Key words: phase II, lododoxorubicin, advanced NSCL + colon + breast cancers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.